Is muscle loss with GLP-1 medications worse than with other weight loss methods
The promise of compounded semaglutide has offered a powerful new path to better health for many
With the increasing prevalence of metabolic diseases globally, interventions targeting GLP-1R could play an important role in reducing the burden of these conditions
Ng, M., Emmanuela Gakidou, Lo, J., Abate, Y.H., Cristiana Abbafati, Abbas, N., Mohammadreza Abbasian, Samar Abd ElHafeez, Abdel-Rahman, W.M., Sherief Abd-Elsalam, Abdollahi, A., Meriem Abdoun, Abdulah, D.M., Rizwan Suliankatchi Abdulkader, Abdullahi, A., Abedi, A., Hansani Madushika Abeywickrama, Alemwork Abie, Aboagye, R.G
Safety concerns : Important risks associated with GLP-1 receptor agonists include pancreatitis, gallbladder disease, dehydration leading to acute kidney injury, hypoglycaemia (when used with insulin or sulfonylureas), and potential worsening of diabetic retinopathy with rapid glycaemic improvement
Missing data on key clinical factors (such as body mass index and type 2 diabetes duration) may contribute to residual confounding, leaving uncertainty about whether the observed association is causal
